肺动脉高压治疗新进展

Advances in Therapy of Pulmonary Arterial Hypertension

肺动脉高压是一种高致死性恶性心血管疾病,临床表现为肺动脉压力进行性升高,导致患者血管重构、右心肥大、心功能衰竭甚至死亡。肺动脉高压病因复杂,仍是不能治愈的慢性疾病之一,其治疗是目前研究热点。目前批准的药物包括一氧化氮、环前列腺素、内皮素等途径研发的靶向药物,在临床使用中仅能使患者症状改善并减缓临床恶化速度。随着发病机制研究的不断深入,近年来新兴靶向药物治疗、经皮肺动脉去神经治疗等方面的进展为治疗肺动脉高压提供了新的方向。

Pulmonary arterial hypertension（ PAH） is a kind of malignant and fatal cardiovascular disease,clinically characterized by progressive pulmonary artery pressure,leading to vascular remodeling,right heart hypertrophy,heart failure,or even death. Because of the pathogenesis complexity of PAH,it is still one of incurable chronic disease and is in hot studying. Currently targeted ways of approved drugs,including nitric oxide,prostacyclin,endothelin and others,only can improve clinical symptoms and reduce the deterioration. Presently with the study of pathogenesis deeply,there are some emerging treatments of PAH,such as novel targeted drug therapy,percutaneous pulmonary artery denervation and so on.